Gynäkologie Kompetenzzentrum Stralsund: gSUND

Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry (2024) Hartkopf AD, Walter CB, Kolberg HC, Hadji P, Tesch H, Fasching P, Ettl J, et al. Journal article Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT (2022) Engler T, Fasching P, Lueftner D, Hartkopf AD, Mueller V, Kolberg HC, Hadji P, et al. Journal article Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status (2021) Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran FA, Overkamp F, et al. Journal article Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011)) (2021) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article, Erratum Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article Therapy landscape in patients with metastatic HER2-positive breast cancer: Data from the PRAEGNANT real-world breast cancer registry (2019) Lux MP, Nabieva N, Hartkopf AD, Huober J, Volz B, Taran FA, Overkamp F, et al. Journal article Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry (2018) Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, et al. Journal article Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry (2018) Mueller V, Nabieva N, Häberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, et al. Journal article